Record 16 New Surgical Facilities, PAT Margin Despite Greenfield Losses

Dr. Agarwal’s Health Care Limited — Q1 FY27 Earnings Call (quarter ended June 30, 2026; held Aug 04, 2026)

1. Overall Tone of Management: Optimistic

• Management opened with “record-breaking results” and “strong start to FY ’27.”
• Repeated confidence language: “remain confident,” “well positioned to carry this momentum,” and “remain committed” to delivery of the full-year facility plan.
• Even when discussing costs, they framed them as expected/contained: PAT margin improved “despite rising greenfield losses.”

2. Key Themes from Management Commentary

• Aggressive greenfield expansion with execution capability
• “Launched 16 new surgical facilities” (record for a single quarter).
• Commissioned “18 new greenfield facilities” in the quarter; total network now 285 facilities across 14 states + 5 UTs.
• Claimed operational maturity: “mastered the playbook of opening and executing greenfield facilities” and “consistent strong patient footfalls from the very early stages.”
• Growth momentum supported by mix shift to high-end procedures
• High-end cataract share: “29.3% of cataract surgeries.”
• Robotic cataract (Femto): “+33.4%” to 1,548 procedures.
• SMILE (SMILE surgeries): “+36.2%.”
• Retinal: “+30%” to 3,861 procedures.
• Same-store sales growth (SSSG) and vintage contribution
• Mature (pre-FY23) cohort: INR 465 cr, +16.3% YoY, 75.9% of group revenue.
• FY24 vintage: INR 48 cr, +19.6%.
• FY25 vintage: INR 62 cr, +38.6%.
• FY26 vintage: INR 33 cr already generated in the quarter.
• Regional traction narrative
• South: +22.8% YoY; “63% of group revenue.”
• North: +50.5% YoY; “9% of group revenue,” with bounce-back in Punjab/J&K after prior disruptions.
• Delhi NCR: hub-and-spoke expansion; “3 to 5 more facilities planned for the remainder of the year.”
• Margin story: profitability improving despite greenfield drag
• EBITDA: INR 177 cr, +25.2% YoY, margin 28.5% (+30 bps).
• PAT margin: 8.9% (+127 bps) “despite rising greenfield losses.”

3. Q&A Analysis

Theme A: Realization / premiumization vs price hike; greenfield losses

• Core questions
• Contribution of case mix (premiumization) and price hikes to value growth.
• Size of losses for newly opened facilities.
• Management response
• Premiumization ~7.5%, price hike ~0.5% → “closer to 8%” total value uplift (like-to-like).
• Greenfield losses: “around INR20 crores at corporate EBITDA level” (includes FY’26 + FY’27 centers and “pre-operating losses”).
• Assessment
• Direct and quantified answers; no obvious evasion.

Theme B: Accounting/finance mechanics (deferred acquisition interest, lease interest)

• Core questions
• Split of interest cost components (lease liability vs deferred acquisition).
• Deferred acquisition “run rate” / impact on finance costs.
• Management response
• Acquisition-related payments: “paid close to INR25 crores” in the quarter.
• Lease liability interest: “around INR18 crores” for Q1.
• Finance cost reduction attributed to deferred acquisition interest dropping (from ~INR6.8 cr to INR3.6 cr) after payments.
• Assessment
• Reasonably transparent; however, the answers emphasize one-off timing effects (payments) rather than underlying cost structure.

Theme C: SSSG drivers (footfall vs value; OPD growth; cohort behavior)

• Core questions
• Footfall growth vs value growth for FY23-and-earlier cohort.
• Whether volume/value split is similar across cohorts.
• Management response
• For SSSG (up to FY23): volume ~8%, value ~8%; value driven by OPD growth and conversion.
• OPD growth/value: “6%” and “another 2%” from conversion.
• For newer vintages, volumes “slightly higher” due to ramp-up.
• Assessment
• Clear breakdown; consistent with prior “premiumization + conversion” narrative.

Theme D: North growth attribution (Delhi NCR vs non-NCR) and maturity gap

• Core questions
• Whether North surgery growth is driven mainly by Delhi NCR or also by smaller markets.
• Surgeries per center vs South “stable state.”
• Management response
• Delhi is a “new entry”: growth this year; last year started with one branch → now seven.
• Punjab bounce-back: prior quarter impacted by “Operation Sindoor and floods.”
• Maturity gap acknowledged: “three years at least” to mature; Delhi “long way” from South maturity.
• Assessment
• Strong qualitative clarity; no hard split of NCR vs non-NCR surgeries, so some quantification is missing.

Theme E: Doctor additions, productivity ramp, attrition

• Core questions
• Whether doctor additions are mainly for new centers and when productivity improves.
• Doctor attrition rate.
• Management response
• Doctor additions largely for new centers; “100 new doctors” in last four months.
• Productivity improvement expected “as time goes by and as the centers start to mature.”
• Attrition: overall 16–17%, senior doctors 2–3%.
• Assessment
• Credible operational explanation; productivity timing remains somewhat open-ended.

Theme F: Realization trajectory sustainability; margin impact of technology

• Core questions
• Will realization growth plateau as base effect fades?
• Will higher-cost technology compress margins?
• Management response
• Realization directionally continues: shift driven by insurance/disposable income and Femto adoption.
• Margin: “Rupee gross margin will definitely go up” (Femto additional charge vs license click fee).
• Assessment
• Strong directional confidence; still lacks a quantified margin sensitivity.

Theme G: Facility launch pace constraints

• Core questions
• Why launch pace can’t be increased beyond current plan.
• Management response
• Bottlenecks: real estate availability/cost and “compliance properties” (local licenses).
• “working on improving the launch pace” and will see ramp in coming quarters.
• Assessment
• Consistent with earlier calls’ compliance/real-estate bottleneck narrative.

Theme H: Merger timeline

• Core questions
• When merger will complete.
• Management response
• Expected completion “around mid-November.”
• Assessment
• Clear update; note that prior guidance had a longer horizon (see consistency section).

4. Guidance / Outlook

Explicit guidance (quantitative)

• Facility additions
• FY’27 plan: started with “plan to add 60 new facilities” (40 surgical centers + 20 clinics implied from earlier framing).
• Q2 outlook: “looking at adding 12 facilities for Q2”
• H2 outlook: “30 in the second half”
• Pipeline: “30-plus signed LOIs already in place”
• Delhi NCR
• “3 to 5 more facilities planned for the remainder of the year”
• Merger
• Completion expected “around mid-November”

Implicit signals (qualitative)

• Growth durability: “sustain the growth momentum” via micro-market penetration, new geographies, and adoption of innovative procedures.
• Margin durability: management expects to “carry this momentum” and highlights EBITDA margin improvement despite greenfield losses.
• Launch pace improvement: “working on improving the launch pace” but constrained by compliance/real estate.

5. Standout Statements (most revealing)

• Expansion intensity
• “16 new surgical facilities… highest ever in a single quarter.”
• “18 greenfield facilities… commissioning… strengthening our reach and capacity.”
• Value growth composition
• “Premiumization… close to around 7.5%” and “price hike… around 0.5%” → “closer to 8%.”
• Greenfield loss magnitude
• “green plot is around close to INR20 crores at corporate EBITDA level… includes pre-operating losses.”
• Maturity gap acknowledged
• “three years at least… from emerging facility to becoming a mature facility… Delhi… long way.”
• Technology margin claim
• “Rupee gross margin will definitely go up” (Femto additional charge vs license click fee).
• Merger timing update
• “expect to close this around mid-November.”

6. Red Flags / Positive Signals (Optional)

Positive signals
– Clear quantification of premiumization vs price hike.
– Senior doctor attrition “2% to 3%” (supports staffing stability).
– Margin improvement despite greenfield losses (PAT margin expansion).

Red flags
– Greenfield losses remain material (“INR20 crores”); profitability is still partly dependent on timing and ramp.
– Several forward-looking items are directional without quantified sensitivities (e.g., realization sustainability, margin impact of technology).
– North growth attribution lacks a hard split between Delhi NCR vs other North markets (analysts pressed for it).

7. Historical Comparison & Consistency Analysis (vs prior 3–4 calls)

a. Change in Tone Over Time

• Current (Q1 FY27): Optimistic—“record-breaking,” “strong start,” “confident on delivering.”
• Prior calls (FY26 Q4 / Q3 / Q2 / Q1 FY26): Also generally optimistic, but more emphasis on “steady momentum” and “in line with guidance.”
• Shift classification: More Optimistic
• Current call adds stronger superlatives (“record-breaking,” “highest ever”) and more confidence around execution (“remain confident,” “engine firing”).
• Less discussion of external headwinds; more focus on internal playbook mastery.

b. Tracking Past Commitments vs Outcomes

1) Merger completion timeline
– Past statement (Aug 12, 2025 Q1 FY26): merger “endeavor to complete… outer limit of next 3 years,” and “next 1–1.5 years” should be possible (Varun Hemant question).
– Past statement (May 21, 2026 Q4 FY26): merger process ongoing; NCLT meetings held July 2, 2026; updates to follow.
– Current (Aug 04, 2026 Q1 FY27): expected to close “around mid-November.”
– Flag: ✅ Delivered / Accelerated relative to “outer limit” framing (though not directly comparable to a specific month earlier, the current date is much more concrete and near-term).

2) Facility launch pace / constraints
– Past (May 21, 2026 Q4 FY26): guidance to add 60 facilities in FY’27; “looking ahead” Q2 and H2 numbers were not as detailed then.
– Current: provides specific cadence: 12 in Q2 and 30 in H2, plus “30-plus signed LOIs.”
– Flag: ✅ More specific delivery; no evidence of missed pace in this quarter (Q1 already launched 16 surgical facilities).

3) Greenfield loss expectations
– Past (May 21, 2026 Q4 FY26): FY’26 greenfield cohort losses “around INR30 crores” (unit economics drag).
– Current: greenfield losses for new facilities “around INR20 crores” (corporate EBITDA level; includes FY’26 + FY’27 centers).
– Flag: ✅ Improving / lower drag (or at least not worsening), but note the definition differs (includes different cohorts and “corporate EBITDA level”).

c. Narrative Shifts

• From “Delhi entry ramp-up” to “Delhi hub-and-spoke scaling”
• Earlier calls emphasized entry and early traction; now management talks about “3 to 5 more facilities planned” and acknowledges maturity gap vs South.
• Technology narrative intensifies
• Femto/SMILE/retinal growth is more prominent now, with explicit margin mechanics (gross margin “definitely go up”).
• Margin explanation becomes more finance-mechanics driven
• Q1 FY27 Q&A focused on deferred acquisition interest and lease interest—suggesting finance cost optics are a key driver of profitability.

d. Consistency & Credibility Signals

• Credibility: Medium to High
• Consistent operational story: greenfield playbook + premiumization + conversion.
• Finance cost explanations are consistent with prior “deferred consideration interest declining as payments made.”
• However, some analyst asks for quant splits (North NCR vs non-NCR) and management stays qualitative—limits verification.

e. Evolution of Key Themes

• Expansion / greenfield: Improving / accelerating (Q1 FY27 record surgical openings; LOIs and cadence emphasized).
• Margins: Stable to improving (EBITDA margin up 30 bps; PAT margin up 127 bps).
• Premiumization: Strengthening (premiumization ~7.5% now quantified; Femto and high-end share rising).
• Refractive growth: Not a major negative in this quarter, but management continues to frame it as technology/insurance adoption-driven rather than purely volume-led.

f. Additional Insights (Cross-Period Intelligence)

• Greenfield losses remain a recurring “known drag,” but management is increasingly quantifying it and tying it to ramp expectations—suggesting they are managing investor expectations more actively.
• Finance cost optics are improving due to payment timing (deferred acquisition interest reduction). This can create “clean” margin quarters even if operating leverage is still ramping—worth monitoring in subsequent quarters.